The graph structure of biomedical data differs from those in typical knowledge graph benchmark tasks. A particular property of biomedical data is the presence of long-range dependencies, which can be captured by patterns described as logical rules. We propose a novel method that combines these rules with a neural multi-hop reasoning approach that uses reinforcement learning. We conduct an empirical study based on the real-world task of drug repurposing by formulating this task as a link prediction problem. We apply our method to the biomedical knowledge graph Hetionet and show that our approach outperforms several baseline methods.
Université de Paris（巴黎大学）；Inserm（法国国家健康与医学研究院）；Université Lille（里尔大学）；CNRS（法国国家科学研究中心）；Inria（法国国家信息与自动化研究所）；Centrale Lille（里尔中央理工学院）；Université Sorbonne Paris Nord（巴黎第十三大学）；Assistance Publique des Hôpitaux de Paris（巴黎公共医疗援助医院）
Motivated by an application to drug repurposing, we propose the first algorithms to tackle the identification of the m $\ge$ 1 arms with largest means in a linear bandit model, in the fixed-confidence setting. These algorithms belong to the generic family of Gap-Index Focused Algorithms (GIFA) that we introduce for Top-m identification in linear bandits. We propose a unified analysis of these algorithms, which shows how the use of features might decrease the sample complexity. We further validate these algorithms empirically on simulated data and on a simple drug repurposing task.
Drug repurposing is more relevant than ever due to drug development's rising costs and the need to respond to emerging diseases quickly. Knowledge graph embedding enables drug repurposing using heterogeneous data sources combined with state-of-the-art machine learning models to predict new drug-disease links in the knowledge graph. As in many machine learning applications, significant work is still required to understand the predictive models' behavior. We propose a structured methodology to understand better machine learning models' results for drug repurposing, suggesting key elements of the…
Predicting interactions among heterogenous graph structured data has numerous applications such as knowledge graph completion, recommendation systems and drug discovery. Often times, the links to be predicted belong to rare types such as the case in repurposing drugs for novel diseases. This motivates the task of few-shot link prediction. Typically, GCNs are ill-equipped in learning such rare link types since the relation embedding is not learned in an inductive fashion. This paper proposes an inductive RGCN for learning informative relation embeddings even in the few-shot learning regime. The…
Drug repurposing is an effective strategy to identify new uses for existing drugs, providing the quickest possible transition from bench to bedside. Existing methods for drug repurposing that mainly focus on pre-clinical information may exist translational issues when applied to human beings. Real world data (RWD), such as electronic health records and insurance claims, provide information on large cohorts of users for many drugs. Here we present an efficient and easily-customized framework for generating and testing multiple candidates for drug repurposing using a retrospective analysis of RW…
Knowledge graph (KG) is used to represent data in terms of entities and structural relations between the entities. This representation can be used to solve complex problems such as recommendation systems and question answering. In this study, a set of candidate drugs for COVID-19 are proposed by using Drug repurposing knowledge graph (DRKG). DRKG is a biological knowledge graph constructed using a vast amount of open source biomedical knowledge to understand the mechanism of compounds and the related biological functions. Node and relation embeddings are learned using knowledge graph embedding…
DrugReason: Dynamic Multi-View Reasoning over Knowledge Graph and Language Evidence for Drug Repurposing
University of North Carolina at Chapel Hill（北卡罗来纳大学教堂山分校）；Stevens Institute of Technology（史蒂文斯理工学院）；Emory University（埃默里大学）；Massachusetts Institute of Technology（麻省理工学院）
Hunan University（湖南大学）；Xiangtan University（湘潭大学）；Central South University（中南大学）；University of Illinois at Chicago（伊利诺伊大学芝加哥分校）；Lehigh University（理海大学）；Frederick National Laboratory for Cancer Research（弗雷德里克国家癌症研究实验室）；National Cancer Institute（国家癌症研究所）；Tel Aviv University（特拉维夫大学）；Cleveland Clinic（克利夫兰诊所）；Case Western Reserve University（凯斯西储大学）
Drug development is time-consuming and expensive. Repurposing existing drugs for new therapies is an attractive solution that accelerates drug development at reduced experimental costs, specifically for Coronavirus Disease 2019 (COVID-19), an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, comprehensively obtaining and productively integrating available knowledge and big biomedical data to effectively advance deep learning models is still challenging for drug repurposing in other complex diseases. In this review, we introduce guidelines on ho…
The size and quality of chemical libraries to the drug discovery pipeline are crucial for developing new drugs or repurposing existing drugs. Existing techniques such as combinatorial organic synthesis and High-Throughput Screening usually make the process extraordinarily tough and complicated since the search space of synthetically feasible drugs is exorbitantly huge. While reinforcement learning has been mostly exploited in the literature for generating novel compounds, the requirement of designing a reward function that succinctly represents the learning objective could prove daunting in ce…
The Corona Virus Disease 2019 (COVID-19) belongs to human coronaviruses (HCoVs), which spreads rapidly around the world. Compared with new drug development, drug repurposing may be the best shortcut for treating COVID-19. Therefore, we constructed a comprehensive heterogeneous network based on the HCoVs-related target proteins and use the previously proposed deepDTnet, to discover potential drug candidates for COVID-19. We obtain high performance in predicting the possible drugs effective for COVID-19 related proteins. In summary, this work utilizes a powerful heterogeneous network-based deep …
The integration of machine learning methods into bioinformatics provides particular benefits in identifying how therapeutics effective in one context might have utility in an unknown clinical context or against a novel pathology. We aim to discover the underlying associations between viral proteins and antiviral therapeutics that are effective against them by employing neural network models. Using the National Center for Biotechnology Information virus protein database and the DrugVirus database, which provides a comprehensive report of broad-spectrum antiviral agents (BSAAs) and viruses they …
The 2019 novel coronavirus (SARS-CoV-2) pandemic has resulted in more than a million deaths, high morbidities, and economic distress worldwide. There is an urgent need to identify medications that would treat and prevent novel diseases like the 2019 coronavirus disease (COVID-19). Drug repurposing is a promising strategy to discover new medical indications of the existing approved drugs due to several advantages in terms of the costs, safety factors, and quick results compared to new drug design and discovery. In this work, we explore computational data-driven methods for drug repurposing and …
IBM Research（IBM研究院）；University of Melbourne（墨尔本大学）；Cures Within Reach for Cancer（癌症可及疗法组织）；Massachusetts Institute of Technology（麻省理工学院）；Harvard Medical School（哈佛医学院）
More than 200 generic drugs approved by the U.S. Food and Drug Administration for non-cancer indications have shown promise for treating cancer. Due to their long history of safe patient use, low cost, and widespread availability, repurposing of generic drugs represents a major opportunity to rapidly improve outcomes for cancer patients and reduce healthcare costs worldwide. Evidence on the efficacy of non-cancer generic drugs being tested for cancer exists in scientific publications, but trying to manually identify and extract such evidence is intractable. In this paper, we introduce a system…
University of Minnesota（明尼苏达大学）；University of Virginia（弗吉尼亚大学）
Knowledge graphs (KGs) are powerful tools that codify relational behaviour between entities in knowledge bases. KGs can simultaneously model many different types of subject-predicate-object and higher-order relations. As such, they offer a flexible modeling framework that has been applied to many areas, including biology and pharmacology -- most recently, in the fight against COVID-19. The flexibility of KG modeling is both a blessing and a challenge from the learning point of view. In this paper we propose a novel coupled tensor-matrix framework for KG embedding. We leverage tensor factorizat…
Towards a more inductive world for drug repurposing approaches
CIMA University of Navarra（纳瓦拉大学CIMA）；IdiSNA（纳瓦拉卫生研究所（IdiSNA））；TECNUN, University of Navarra（纳瓦拉大学TECNUN）；Stanford Center for Biomedical Informatics Research, Stanford University（斯坦福大学生物医学信息学研究中心）；Ghent University（根特大学）；Instituto de Ciencia de los Datos e Inteligencia Artificial (DATAI), University of Navarra（纳瓦拉大学数据科学与人工智能研究所（DATAI））
Northeastern University（东北大学）；Brigham and Women’s Hospital（布莱根妇女医院）；Harvard Medical School（哈佛医学院）；Harvard University（哈佛大学）；Scipher Medicine；Sabanci University（萨班哲大学）；Boston University（波士顿大学）；Central European University（中欧大学）
The current pandemic has highlighted the need for methodologies that can quickly and reliably prioritize clinically approved compounds for their potential effectiveness for SARS-CoV-2 infections. In the past decade, network medicine has developed and validated multiple predictive algorithms for drug repurposing, exploiting the sub-cellular network-based relationship between a drug's targets and disease genes. Here, we deployed algorithms relying on artificial intelligence, network diffusion, and network proximity, tasking each of them to rank 6,340 drugs for their expected efficacy against SAR…
The University of Texas Health Science Center at Houston（德克萨斯大学休斯顿健康科学中心）；University of Helsinki（赫尔辛基大学）
Amid the pandemic of 2019 novel coronavirus disease (COVID-19) infected by SARS-CoV-2, a vast amount of drug research for prevention and treatment has been quickly conducted, but these efforts have been unsuccessful thus far. Our objective is to prioritize repurposable drugs using a drug repurposing pipeline that systematically integrates multiple SARS-CoV-2 and drug interactions, deep graph neural networks, and in-vitro/population-based validations. We first collected all the available drugs (n= 3,635) involved in COVID-19 patient treatment through CTDbase. We built a SARS-CoV-2 knowledge gra…
Beijing Institute of Pharmacology and Toxicology（北京药物研究所）；Beihang University（北京航空航天大学）；PLA General Hospital（中国人民解放军总医院）；Chengdu Jianshu Technology Co. Ltd（成都建数科技有限公司）
The novel coronavirus disease, named COVID-19, emerged in China in December 2019, and has rapidly spread around the world. It is clearly urgent to fight COVID-19 at global scale. The development of methods for identifying drug uses based on phenotypic data can improve the efficiency of drug development. However, there are still many difficulties in identifying drug applications based on cell picture data. This work reported one state-of-the-art machine learning method to identify drug uses based on the cell image features of 1024 drugs generated in the LINCS program. Because the multi-dimensio…
Ludwig Maximilian University of Munich（慕尼黑大学）；Siemens（西门子公司）；Siemens Healthineers（西门子医疗）
Biomedical knowledge graphs permit an integrative computational approach to reasoning about biological systems. The nature of biological data leads to a graph structure that differs from those typically encountered in benchmarking datasets. To understand the implications this may have on the performance of reasoning algorithms, we conduct an empirical study based on the real-world task of drug repurposing. We formulate this task as a link prediction problem where both compounds and diseases correspond to entities in a knowledge graph. To overcome apparent weaknesses of existing algorithms, we …
Mila, the Quebec AI Institute（米拉魁北克人工智能研究所）；Relation Therapeutics（Relation Therapeutics公司）；The Scripps Research Institute（斯克里普斯研究所）；Glyde Bio, Inc（Glyde生物公司）；IRIC, Institute for Research in Immunology and Cancer, Université de Montréal（蒙特利尔大学免疫学与癌症研究所（IRIC））；University of Oxford（牛津大学）；Twitter（推特）
For large libraries of small molecules, exhaustive combinatorial chemical screens become infeasible to perform when considering a range of disease models, assay conditions, and dose ranges. Deep learning models have achieved state of the art results in silico for the prediction of synergy scores. However, databases of drug combinations are biased towards synergistic agents and these results do not necessarily generalise out of distribution. We employ a sequential model optimization search utilising a deep learning model to quickly discover synergistic drug combinations active against a cancer …
Coupled Tensor-Tensor Completion Method with Applications in Drug Repurposing
Idaho State University（爱达荷州立大学）；Massachusetts Institute of Technology（麻省理工学院）；University of Michigan（密歇根大学）；Statistics Online Computational Resource (SOCR)（统计在线计算资源（SOCR））
Stony Brook University（石溪大学）；Allen Institute for Artificial Intelligence（艾伦人工智能研究所）
Question Answering (QA) naturally reduces to an entailment problem, namely, verifying whether some text entails the answer to a question. However, for multi-hop QA tasks, which require reasoning with multiple sentences, it remains unclear how best to utilize entailment models pre-trained on large scale datasets such as SNLI, which are based on sentence pairs. We introduce Multee, a general architecture that can effectively use entailment models for multi-hop QA tasks. Multee uses (i) a local module that helps locate important sentences, thereby avoiding distracting information, and (ii) a glob…
Inria Saclay（法国国家信息与自动化研究所萨克莱分所）；Univ. Paris Saclay（巴黎萨克雷大学）；IIIT - Delhi（德里英迪拉·甘地信息技术学院）
Co-administration of two or more drugs simultaneously can result in adverse drug reactions. Identifying drug-drug interactions (DDIs) is necessary, especially for drug development and for repurposing old drugs. DDI prediction can be viewed as a matrix completion task, for which matrix factorization (MF) appears as a suitable solution. This paper presents a novel Graph Regularized Probabilistic Matrix Factorization (GRPMF) method, which incorporates expert knowledge through a novel graph-based regularization strategy within an MF framework. An efficient and sounded optimization algorithm is pro…
Tulane Center for Biomedical Informatics and Genomics（杜兰大学生物医学信息学与基因组学中心）；Division of Biomedical Informatics and Genomics（生物医学信息学与基因组学部门）；Deming Department of Medicine（戴明医学系）；Tulane University（杜兰大学）
Many statistical machine approaches could ultimately highlight novel features of the etiology of complex diseases by analyzing multi-omics data. However, they are sensitive to some deviations in distribution when the observed samples are potentially contaminated with adversarial corrupted outliers (e.g., a fictional data distribution). Likewise, statistical advances lag in supporting comprehensive data-driven analyses of complex multi-omics data integration. We propose a novel non-linear M-estimator-based approach, "robust kernel machine regression (RobKMR)," to improve the robustness of stati…
A pharmacological effect of a drug on cells, organs and systems refers to the specific biochemical interaction produced by a drug substance, which is called its mechanism of action. Drug repositioning (or drug repurposing) is a fundamental problem for the identification of new opportunities for the use of already approved or failed drugs. In this paper, we present a method based on a multi-relation unsupervised graph embedding model that learns latent representations for drugs and diseases so that the distance between these representations reveals repositioning opportunities. Once representati…
Predicting the interaction between a compound and a target is crucial for rapid drug repurposing. Deep learning has been successfully applied in drug-target affinity (DTA) problem. However, previous deep learning-based methods ignore modeling the direct interactions between drug and protein residues. This would lead to inaccurate learning of target representation which may change due to the drug binding effects. In addition, previous DTA methods learn protein representation solely based on a small number of protein sequences in DTA datasets while neglecting the use of proteins outside of the D…
The US Food and Drug Administration (FDA) has been actively promoting the use of real-world data (RWD) in drug development. RWD can generate important real-world evidence reflecting the real-world clinical environment where the treatments are used. Meanwhile, artificial intelligence (AI), especially machine- and deep-learning (ML/DL) methods, have been increasingly used across many stages of the drug development process. Advancements in AI have also provided new strategies to analyze large, multidimensional RWD. Thus, we conducted a rapid review of articles from the past 20 years, to provide a…
Motivation: Predicting the drug-target interaction is crucial for drug discovery as well as drug repurposing. Machine learning is commonly used in drug-target affinity (DTA) problem. However, machine learning model faces the cold-start problem where the model performance drops when predicting the interaction of a novel drug or target. Previous works try to solve the cold start problem by learning the drug or target representation using unsupervised learning. While the drug or target representation can be learned in an unsupervised manner, it still lacks the interaction information, which is cr…
Indian Association for the Cultivation of Science（印度科学培育协会）
Development of new drugs is an expensive and time-consuming process. Due to the world-wide SARS-CoV-2 outbreak, it is essential that new drugs for SARS-CoV-2 are developed as soon as possible. Drug repurposing techniques can reduce the time span needed to develop new drugs by probing the list of existing FDA-approved drugs and their properties to reuse them for combating the new disease. We propose a novel architecture DeepGLSTM, which is a Graph Convolutional network and LSTM based method that predicts binding affinity values between the FDA-approved drugs and the viral proteins of SARS-CoV-2…
Relation Therapeutics（Relay Therapeutics（注：原文为Relation Therapeutics，直译：关系治疗公司））；University of Cambridge（剑桥大学）；Juvenescence（Juvenescence公司）；Mila, the Quebec AI Institute（米拉魁北克人工智能研究所）；HEC Montreal（蒙特利尔高等商学院）；The Francis Crick Institute（弗朗西斯·克里克研究所）；Imperial College London（帝国理工学院）；Twitter（推特）
Graph Machine Learning (GML) is receiving growing interest within the pharmaceutical and biotechnology industries for its ability to model biomolecular structures, the functional relationships between them, and integrate multi-omic datasets - amongst other data types. Herein, we present a multidisciplinary academic-industrial review of the topic within the context of drug discovery and development. After introducing key terms and modelling approaches, we move chronologically through the drug development pipeline to identify and summarise work incorporating: target identification, design of sma…
Learning unsupervised node embeddings facilitates several downstream tasks such as node classification and link prediction. A node embedding is universal if it is designed to be used by and benefit various downstream tasks. This work introduces PanRep, a graph neural network (GNN) model, for unsupervised learning of universal node representations for heterogenous graphs. PanRep consists of a GNN encoder that obtains node embeddings and four decoders, each capturing different topological and node feature properties. Abiding to these properties the novel unsupervised framework learns universal e…
VitaGraph: Building a Knowledge Graph for Biologically Relevant Learning Tasks
DIAG, Sapienza University of Rome（Sapienza罗马大学DIAG部门）；IAC, CNR Consiglio Nazionale delle Ricerche（CNR国家研究委员会IAC部门）；Department of Biochemical Sciences（生物化学系）；Sapienza University of Rome（Sapienza罗马大学）；Department of Life Science Informatics and Data Science（生命科学信息学与数据科学系）；University of Bonn（波恩大学）；Lamarr Institute（拉玛尔研究所）；DIET, Sapienza University of Rome（Sapienza罗马大学DIET部门）
ELLIS Unit at the LIT AI Lab, Johannes Kepler University Linz（林茨约翰内斯·开普勒大学 LIT AI 实验室 ELLIS 单元）；Institute for Machine Learning, Johannes Kepler University Linz（林茨约翰内斯·开普勒大学机器学习研究所）
Due to the current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, there is an urgent need for novel therapies and drugs. We conducted a large-scale virtual screening for small molecules that are potential CoV-2 inhibitors. To this end, we utilized "ChemAI", a deep neural network trained on more than 220M data points across 3.6M molecules from three public drug-discovery databases. With ChemAI, we screened and ranked one billion molecules from the ZINC database for favourable effects against CoV-2. We then reduced the result to the 30,000 top-ranked compounds, which are …
School of Computer Science and Engineering, Hunan University（湖南大学计算机科学与工程学院）；AWS Shanghai AI Lab（亚马逊云科技上海人工智能实验室）；Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic（克利夫兰诊所勒纳研究所基因组医学研究所）；New York University Shanghai（上海纽约大学）；AWS AI（亚马逊云科技人工智能部门）；University of Minnesota（明尼苏达大学）；Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University（凯斯西储大学克利夫兰诊所勒纳医学院分子医学系）；Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine（凯斯西储大学医学院凯斯综合癌症中心）
There have been more than 850,000 confirmed cases and over 48,000 deaths from the human coronavirus disease 2019 (COVID-19) pandemic, caused by novel severe acute respiratory syndrome coronavirus (SARS-CoV-2), in the United States alone. However, there are currently no proven effective medications against COVID-19. Drug repurposing offers a promising way for the development of prevention and treatment strategies for COVID-19. This study reports an integrative, network-based deep learning methodology to identify repurposable drugs for COVID-19 (termed CoV-KGE). Specifically, we built a comprehe…
University of Texas Health Science Center at Houston（德克萨斯大学休斯顿健康科学中心）
Developing new drugs for target diseases is a time-consuming and expensive task, drug repurposing has become a popular topic in the drug development field. As much health claim data become available, many studies have been conducted on the data. The real-world data is noisy, sparse, and has many confounding factors. In addition, many studies have shown that drugs effects are heterogeneous among the population. Lots of advanced machine learning models about estimating heterogeneous treatment effects (HTE) have emerged in recent years, and have been applied to in econometrics and machine learnin…
Boosting drug-disease association prediction for drug repositioning via dual-feature extraction and cross-dual-domain decoding
Institute of Computing Science and Technology, Guangzhou University（广州大学计算科学与技术学院）；School of Computer Science and Technology, Dalian University of Technology（大连理工大学计算机科学与技术学院）；Electronics and Communication Sciences Unit, Indian Statistical Institute（印度统计研究所电子与通信科学部）
LLM$^3$-DTI: A Large Language Model and Multi-modal data co-powered framework for Drug-Target Interaction prediction
Polytechnic Institute（多技术学院）；School of Pharmaceutical Sciences（药学学院）；Innovation Center of Yangtze River Delta（长江三角洲创新中心）；Agricultural Genomics Institute at Shenzhen（深圳农业基因组研究院）；School of Public Health（公共卫生学院）
University of Washington（华盛顿大学）；Allen Institute for Artificial Intelligence (AI2)（艾伦人工智能研究所）
Biomedical knowledge graphs (KGs) hold rich information on entities such as diseases, drugs, and genes. Predicting missing links in these graphs can boost many important applications, such as drug design and repurposing. Recent work has shown that general-domain language models (LMs) can serve as "soft" KGs, and that they can be fine-tuned for the task of KG completion. In this work, we study scientific LMs for KG completion, exploring whether we can tap into their latent knowledge to enhance biomedical link prediction. We evaluate several domain-specific LMs, fine-tuning them on datasets cent…
